TAK-721 FDA Approval Status
Last updated by Judith Stewart, BPharm on Dec 16, 2020.
TAK-721 (budesonide oral suspension) is a novel mucoadherent topically active oral viscous formulation of budesonide in development as a treatment for eosinophilic esophagitis (EoE).
Development timeline for TAK-721
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.